Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 39 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

455 Second primary malignancy risk in the immunotherapy era among urothelial carcinoma survivors: a SEER population-based analysis

  • Jeffrey Afrifa-Yamoah1
  • Damilola Ologbe1
  • Duresha Malik2
  • Michael Asare3
  • Josephine Poku-Adusei4
  • Olanipekun Lanny Ntukidem2
  • Stanley Emmanuel Atencah5
  • Ayodeji Johnson6
  • Nnamdi Omenuko7
7 affiliations
  1. 1Trinity Health Ann Arbor Hospital, Ann Arbor, MI, USA
  2. 2Trinity Health Ann Arbor, Ann Arbor, MI, USA
  3. 3BronxCare Health System, Bronx, NY, USA
  4. 4Haywood Regional Medical Center, Clyde, NC, USA
  5. 5Piedmont Athens Regional Medical Center, Athens, GA, USA
  6. 6Boston Medical Centre, Boston, MA, USA
  7. 7East Tennessee State University, Johnson City, TN, USA
Open at sourceDOICite

Related

  1. A urothelial cell carcinoma in the abdominal cavity after salpingectomy for tubo-ovarian carcinoma risk reduction in a
    Tamar A. Gootzen, Alda Birgsdottir, Miranda P. Steenbeek +4
    Gynecologic Oncology ReportsPeer-reviewedCC BY-NC-NDFull textGenetics & genomicsDOAJEurope PMCPMC
  2. 454 Second primary hematologic malignancies in melanoma survivors before and after the introduction of immune checkpoint inhibitors: a population-based SEER analysis
    Jeffrey Afrifa-Yamoah, Damilola Ologbe, Duresha Malik +5
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  3. Spatiotemporal remodeling of the tumor–immune interface during neoadjuvant immunotherapy for oral squamous cell carcinoma: pathological response, resistance, and dynamic biomarkers
    Jingnan Xue, Tingting Jia, Jiaxiang Yu +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyCrossref
  4. Interleukin-33 alleviates the immunosuppressive tumor microenvironment and enhances anti-programmed death ligand-1 immunotherapy efficacy in hepatocellular carcinoma
    Ensi Ma, Yange Gu, Weiqiao He +6
    Chinese Medical JournalPeer-reviewedCC BY-NC-ND 4.0Full textImmunologyPMC
  5. Crucial Role of Lymphocytes in the Therapeutic Efficacy of Dendritic Cell Immunotherapy for Advanced Hepatocellular Carcinoma
    Wei-Chen Lee, Yin Lai, Hao-Chien Hung +8
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0ImmunologyCrossref

Cite

BibTeXRIS
BibTeX
@article{afrifayamoah2026second,
  title = {{455 Second primary malignancy risk in the immunotherapy era among urothelial carcinoma survivors: a SEER population-based analysis}},
  author = {Jeffrey Afrifa-Yamoah and Damilola Ologbe and Duresha Malik and Michael Asare and Josephine Poku-Adusei and Olanipekun Lanny Ntukidem and Stanley Emmanuel Atencah and Ayodeji Johnson and Nnamdi Omenuko},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0455},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0455},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 455 Second primary malignancy risk in the immunotherapy era among urothelial carcinoma survivors: a SEER population-based analysis
AU  - Jeffrey Afrifa-Yamoah
AU  - Damilola Ologbe
AU  - Duresha Malik
AU  - Michael Asare
AU  - Josephine Poku-Adusei
AU  - Olanipekun Lanny Ntukidem
AU  - Stanley Emmanuel Atencah
AU  - Ayodeji Johnson
AU  - Nnamdi Omenuko
PY  - 2026
DA  - 2026/11/04
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0455
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0455
SN  - 2051-1426
ER  -